Source
came out of India:
The patient was a 53-year-old female with a two-year history of progressively increasing abdominal distension, recently associated with abdominal discomfort and constipation. She had no history of hematuria or flank pain, the other two components of the classic triad of kidney tumors. The examination revealed a firm, painless lump in the left abdomen crossing the midline, with reduced mobility. No abnormalities were detected during the systemic examination. She had no known comorbidities or significant family history. Haematological assessment revealed a haemoglobin level of 10.1 g/dL. Serum renal and hepatic function tests were within normal limits.
Abdominal ultrasound revealed a large, heterogeneous mass measuring 18 cm × 16 cm originating from the lower pole of the left kidney. CT urography showed a large, heterogeneous, mostly unenhanced lesion with enhanced solid components originating from the lower and middle poles of the left kidney, measuring 25 cm × 23 cm × 18 cm. There was no evidence of direct invasion of the renal vein or inferior vena cava, and no lymph node metastasis was observed. The chest CT was negative for metastatic disease (Figure 1).
The patient was counselled on the planned surgical procedure and associated perioperative risks, and written informed consent was obtained. She then underwent a left radical nephrectomy opened by a median transperitoneal approach. Upon entering the peritoneal cavity, a massive retroperitoneal tumor originating in the left kidney was identified. The descending colon was medially mobilized from the rectosigmoid junction to the splenic flexion, facilitating the circular dissection of the tumor from the surrounding structures and the overlying mesentery.
Identification of the renal hilum was technically difficult due to the extreme size and weight of the tumor. The marked left gonadal vessels were identified and followed upwards to facilitate the location of the renal hilum. A single dilated renal vein and a single normal-caliber renal artery were identified. The renal vein was carefully examined to its junction with the inferior vena cava, with no evidence of tumor thrombus. The renal artery was clamped and divided, followed by secure closure and division of the renal vein using polypropylene sutures. The ureter was then clamped and divided, and the kidney with the tumor was carefully mobilized from the surrounding structures and removed en bloc.
The resected specimen measured approximately 30 cm × 28 cm and weighed 8.2 kg immediately after surgery (Figure 2). The difference between the in vivo radiological measurement and the ex vivo crude specimen measurement is due to tissue relaxation and the inclusion of surrounding perirenal tissue in the block specimen. Two enlarged left para-aortic lymph nodes identified during the operation were excised and sent for histopathological examination. Despite compression of the left renal vein by the massive tumor, no evidence of renal vein thrombosis or abrupt invasion of adjacent structures was observed. Careful hemostasis was performed, a 24-Fr abdominal drain was placed, and the abdominal wall was closed in layers.
The postoperative period was uneventful. The urethral catheter was removed on the 2nd postoperative day, and the abdominal drain was removed on the 3rd postoperative day. Her postoperative hemoglobin was 9.8 g/dL, and urine production remained adequate throughout the recovery period. Histopathological examination revealed clear cell RCC, nuclear grade 1 according to the WHO/International Society of Urological Pathology (ISUP), with focal tumor necrosis and no lymphovascular invasion or lymph node metastasis. According to the classification of tumors, lymph nodes, metastases (TNM), the tumor was classified as pT2bN0M0 (Stage II). After discussion with the patient and a medical oncologist, it was concluded that radical nephrectomy was the appropriate treatment in accordance with the National Comprehensive Cancer Network (NCCN) guidelines. No adjuvant therapy was considered necessary at this stage. The patient was scheduled for monitoring based on NCCN recommendations, including annual clinical and laboratory evaluation, computed tomography/abdominal MRI with contrast every six months for the first two years, followed by annual imaging for up to five years or longer if clinically indicated, and annual chest imaging for at least five years.